Based on the Lupin Limited stock forecast from 6 analysts, the average analyst target price for Lupin Limited is INR 2,334.00 over the next 12 months. Lupin Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Lupin Limited is Neutral, which is based on 7 positive signals and 7 negative signals. At the last closing, Lupin Limited’s stock price was INR 2,368.85. Lupin Limited’s stock price has changed by +6.33% over the past week, +13.80% over the past month and +68.43% over the last year.
No recent analyst target price found for Lupin Limited
No recent average analyst rating found for Lupin Limited
Company Overview Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India. Read Less
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialt...Read More
Frequently Asked Questions About Lupin Limited (LUPIN:NSE) Stock
Based on ratings from 6 analysts Lupin Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 7 buy, 1 sell and 1 hold ratings.
LUPIN:NSE stock's dividend yield is 0.36%.
Our analysis grades LUPIN:NSE stock's dividend yield at F. This means that LUPIN:NSE stock's dividend yield is above 49% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this LUPIN:NSE may be a average dividend stock for its sector.
Based on targets from 6 analysts, the average taret price for LUPIN:NSE is INR 2,334.00 over the next 12 months. The maximum analyst target price is INR 2750 while the minimum anlayst target price is INR 1615.
LUPIN:NSE stock's Price/Earning ratio is 38.76.
Our analysis grades LUPIN:NSE stock's Price / Earning ratio at F. This means that LUPIN:NSE stock's Price/Earning ratio is above 42.00000000000001% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this LUPIN:NSE may be fairly valued for its sector
The last closing price of LUPIN:NSE's stock was INR 2,368.85.
The most recent market capitalization for LUPIN:NSE is INR 1,016.49B.
Based on targets from 6 analysts, the average taret price for LUPIN:NSE is projected at INR 2,334.00 over the next 12 months.
This means that LUPIN:NSE's stock price may go down by -1.47% over the next 12 months.
We can't find any ETFs which contains Lupin Limited's stock.
As per our most recent records Lupin Limited has 19,210 Employees.
Lupin Limited's registered address is Kalpataru Inspire, Mumbai, India, 400055.
You can get more information about it from Lupin Limited's website at https://www.lupin.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Lupin Limited (LUPIN:NSE) Stock
Based on ratings from 6 analysts Lupin Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 7 buy, 1 sell and 1 hold ratings.
LUPIN:NSE stock's dividend yield is 0.36%.
Our analysis grades LUPIN:NSE stock's dividend yield at F. This means that LUPIN:NSE stock's dividend yield is above 49% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this LUPIN:NSE may be a average dividend stock for its sector.
Based on targets from 6 analysts, the average taret price for LUPIN:NSE is INR 2,334.00 over the next 12 months. The maximum analyst target price is INR 2750 while the minimum anlayst target price is INR 1615.
LUPIN:NSE stock's Price/Earning ratio is 38.76.
Our analysis grades LUPIN:NSE stock's Price / Earning ratio at F. This means that LUPIN:NSE stock's Price/Earning ratio is above 42.00000000000001% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this LUPIN:NSE may be fairly valued for its sector
The last closing price of LUPIN:NSE's stock was INR 2,368.85.
The most recent market capitalization for LUPIN:NSE is INR 1,016.49B.
Based on targets from 6 analysts, the average taret price for LUPIN:NSE is projected at INR 2,334.00 over the next 12 months.
This means that LUPIN:NSE's stock price may go down by -1.47% over the next 12 months.
We can't find any ETFs which contains Lupin Limited's stock.
As per our most recent records Lupin Limited has 19,210 Employees.
Lupin Limited's registered address is Kalpataru Inspire, Mumbai, India, 400055.
You can get more information about it from Lupin Limited's website at https://www.lupin.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LUPIN:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
